<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28657840</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">0967-4845</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>74</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>British journal of biomedical science</Title>
          <ISOAbbreviation>Br J Biomed Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Therapeutic warfarin use and the extrahepatic functions of vitamin K-dependent proteins.</ArticleTitle>
        <Pagination>
          <StartPage>163</StartPage>
          <EndPage>169</EndPage>
          <MedlinePgn>163-169</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/09674845.2017.1336854</ELocationID>
        <Abstract>
          <AbstractText>The impact of warfarin therapy on the functions of extrahepatic vitamin K-dependent proteins (VKDP) is less clearly understood and less widely recognised in clinical practice than that on the hepatic counterparts (clotting factors II, VII, IX and X). Warfarin inhibits osteocalcin, an abundant extrahepatic VKDP involved in the mineralisation and maturation of bone and thus, primarily by this mechanism, may have an adverse effect on bone health. Whilst some studies do link warfarin use to an increase in osteoporosis and fracture risk others have not. Warfarin also inhibits the extrahepatic VKDP matrix gla protein (MGP) which acts to prevent ectopic calcification of the vasculature. Studies have consistently found a correlation between warfarin use and vascular calcification with inhibition of MGP believed to be the main cause. Inhibition of MGP also appears to explain warfarin's well established teratogenic effect. Further adverse effects may also arise from warfarin's inhibition of other known extrahepatic VKDPs. The available evidence is intriguing, and suggests that the impact of warfarin on the extrahepatic functions of vitamin K-dependent proteins warrants further careful consideration.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Donaldson</LastName>
            <ForeName>C J</ForeName>
            <Initials>CJ</Initials>
            <Identifier Source="ORCID">0000-0002-8046-730X</Identifier>
            <AffiliationInfo>
              <Affiliation>a Faculty of Life Sciences and Medicine , King's College London , London , UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Harrington</LastName>
            <ForeName>D J</ForeName>
            <Initials>DJ</Initials>
            <Identifier Source="ORCID">0000-0003-4786-9240</Identifier>
            <AffiliationInfo>
              <Affiliation>b The Nutristasis Unit, Viapath, St. Thomas' Hospital , London , UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>c Division of Women's Health , School of Medicine, King's College London , London , UK.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>06</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Br J Biomed Sci</MedlineTA>
        <NlmUniqueID>9309208</NlmUniqueID>
        <ISSNLinking>0967-4845</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011506">Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>12001-79-5</RegistryNumber>
          <NameOfSubstance UI="D014812">Vitamin K</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5Q7ZVV76EI</RegistryNumber>
          <NameOfSubstance UI="D014859">Warfarin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001842" MajorTopicYN="N">Bone and Bones</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061205" MajorTopicYN="N">Vascular Calcification</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014812" MajorTopicYN="N">Vitamin K</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014859" MajorTopicYN="N">Warfarin</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">MGP</Keyword>
        <Keyword MajorTopicYN="N">Warfarin</Keyword>
        <Keyword MajorTopicYN="N">extra hepatic</Keyword>
        <Keyword MajorTopicYN="N">osteocalcin</Keyword>
        <Keyword MajorTopicYN="N">vitamin K</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28657840</ArticleId>
        <ArticleId IdType="doi">10.1080/09674845.2017.1336854</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
